Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2013 1
2014 1
2015 1
2016 1
2017 2
2018 5
2019 6
2020 3
2021 3
2022 6
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Goldschmidt H, et al. Among authors: gezer d. Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0. Lancet Haematol. 2022. PMID: 36328040 Clinical Trial.
Postoperative Sugillationen und Nekrosen.
Schmidt MF, Megahed M, Peeters TB, Gezer D, Kluwig D, Yazdi AS. Schmidt MF, et al. Among authors: gezer d. J Dtsch Dermatol Ges. 2023 Jan;21(1):74-76. doi: 10.1111/ddg.14918_g. J Dtsch Dermatol Ges. 2023. PMID: 36721927 No abstract available.
Postoperative sugillations and necrosis.
Schmidt MF, Megahed M, Peeters TB, Gezer D, Kluwig D, Yazdi AS. Schmidt MF, et al. Among authors: gezer d. J Dtsch Dermatol Ges. 2023 Jan;21(1):74-76. doi: 10.1111/ddg.14918. J Dtsch Dermatol Ges. 2023. PMID: 36721926 No abstract available.
Real-world analysis of teclistamab in 123 RRMM patients from Germany.
Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A, Einsele H, Faltin J, Frenking J, Gezer D, Goldman-Mazur S, Hänel M, Hoegner M, Kortuem KM, Krönke J, Kull M, Leitner T, Mann C, Mecklenbrauck R, Merz M, Morgner A, Nogai A, Raab MS, Teipel R, Wäsch R, Rasche L. Riedhammer C, et al. Among authors: gezer d. Leukemia. 2024 Feb;38(2):365-371. doi: 10.1038/s41375-024-02154-5. Epub 2024 Jan 20. Leukemia. 2024. PMID: 38245601 Free PMC article.
Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway.
Busch L, Mougiakakos D, Büttner-Herold M, Müller MJ, Volmer DA, Bach C, Fabri M, Bittenbring JT, Neumann F, Boxhammer R, Nolting J, Bisht S, Böttcher M, Jitschin S, Hoffmann MH, Balzer H, Beier F, Gezer D, Dudziak D, Gelse K, Hennig FF, Pallasch CP, Spriewald B, Mackensen A, Bruns H. Busch L, et al. Among authors: gezer d. Leukemia. 2018 Nov;32(11):2445-2458. doi: 10.1038/s41375-018-0114-0. Epub 2018 Mar 28. Leukemia. 2018. PMID: 29654274
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.
Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, Jost PJ, Parmentier S, Schaich M, von Bubnoff N, Stegelmann F, Maurer A, Crysandt M, Gezer D, Kortmann M, Franklin J, Frank J, Hellmich M, Brümmendorf TH; German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Koschmieder S, et al. Among authors: gezer d. Ann Hematol. 2023 Feb;102(2):349-358. doi: 10.1007/s00277-022-05080-7. Epub 2022 Dec 23. Ann Hematol. 2023. PMID: 36564535 Free PMC article. Clinical Trial.
The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling.
Olschok K, Altenburg B, de Toledo MAS, Maurer A, Abels A, Beier F, Gezer D, Isfort S, Paeschke K, Brümmendorf TH, Zenke M, Chatain N, Koschmieder S. Olschok K, et al. Among authors: gezer d. Front Oncol. 2023 Oct 24;13:1277453. doi: 10.3389/fonc.2023.1277453. eCollection 2023. Front Oncol. 2023. PMID: 37941547 Free PMC article.
Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.
Isfort S, Crysandt M, Gezer D, Koschmieder S, Brümmendorf TH, Wolf D. Isfort S, et al. Among authors: gezer d. Recent Results Cancer Res. 2018;212:87-108. doi: 10.1007/978-3-319-91439-8_4. Recent Results Cancer Res. 2018. PMID: 30069626
32 results